Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03939481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Sep 1, 2026 to Feb 1, 2027 Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 7 of 9 entries · Site details revised at 13 of 169 sites Show 3 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 7 of 9 entries
    • Site details revised at 13 of 169 sites
  2. Primary endpoint(s) modified Results first posted: Jun 8, 2026 · Secondary endpoints revised (9)v21 Show 2 more changesShow less
    • Results first posted: Jun 8, 2026
    • Secondary endpoints revised (9)

    See this version in full on ClinicalTrials.gov ↗

  3. Completion date: Feb 28, 2026 to Sep 1, 2026v20
  4. Primary completion date changed from estimate of Sep 15, 2025 to Apr 8, 2025v19
  5. Primary completion date: Aug 28, 2025 to Sep 15, 2025v18
Show 16 earlier versionsHide 16 earlier versions
  1. Primary completion date: Feb 28, 2025 to Aug 28, 2025v17
  2. Re-verified, no change to tracked fieldsv16
  3. Start date: Mar 1, 2019 to May 14, 2019v15
  4. Re-verified, no change to tracked fieldsv14
  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 1050 to confirmed 1336 · Study sites: 153 to 169v13 Show 2 more changesShow less
    • Enrollment target: estimated 1050 to confirmed 1336
    • Study sites: 153 to 169
  6. Study sites: 131 to 153v12
  7. Study sites: 103 to 131v11
  8. Re-verified, no change to tracked fieldsv10
  9. Study sites: 81 to 103 Secondary endpoints revised (9)v9 Show 1 more changeShow less
    • Secondary endpoints revised (9)

    See this version in full on ClinicalTrials.gov ↗

  10. Primary completion date: Aug 1, 2024 to Feb 28, 2025 Completion date: Aug 1, 2025 to Feb 28, 2026v8 Show 1 more changeShow less
    • Completion date: Aug 1, 2025 to Feb 28, 2026
  11. Study sites: 31 to 81v7
  12. Study sites: 20 to 31v6
  13. Study sites: 11 to 20v5
  14. Study sites: 1 to 11v4
  15. 2 versions Re-verified since May 6, 2019, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
SWOG Cancer Research Network
64 trials monitored
See 3 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
and 1 more disease
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Trial Details
NCT Number NCT03939481
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 +38 more
Enrollment 1,336 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov